RNAZ (TransCode Therapeutics) Interest Expense: $-0.01 Mil (TTM As of Mar. 2026)


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $5.24
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Interest Expense?

TransCode Therapeutics RNAZ +8.26% 32 Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus rates RNAZ with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TransCode Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TransCode Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -17.62 Mil. TransCode Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. TransCode Therapeutics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

TransCode Therapeutics  (NAS:RNAZ) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TransCode Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-17.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

TransCode Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

TransCode Therapeutics had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

TransCode Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics Interest Expense Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.10 -0.03 -0.06 -0.03 -0.01

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.01 -0.00 0.00
RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.01 Mil mean?
TransCode Therapeutics (RNAZ) has a Interest Expense of $-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' Interest Expense too high?
TransCode Therapeutics' current Interest Expense is $-0.01 Mil. Overall, TransCode Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Interest Expense compare to ENSC and ALZN?
TransCode Therapeutics' Interest Expense of $-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Interest Expense is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Interest Expense of $-0.01 Mil. The current Interest Expense is $-0.01 Mil. TransCode Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Interest Expense is $-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.24
Price